NEW YORK (GenomeWeb) – Bioinformatics firms Genalice and BioDiscovery announced today that they have signed an agreement to co-promote their respective technologies as a single solution for the interpretation of next-generation sequencing data.
The deal joins Genalice's Map technology, which enables rapid NGS data processing and analysis, with BioDiscovery's NxClinical data visualization platform. According to the companies, the Map technology improves the process of aligning and calling genomes, while NxClinical provides a database for reviewing and reporting combined data of single nucleotide variants, indels, and copy number variations.
Additional terms of the agreement were not disclosed.
"The Genalice and BioDiscovery co-marketing partnership is a response to the rapidly growing volumes and usage of NGS data, which highlights the urgent need for faster processing and interpretation technologies," Michelle Meijer, commercial director at Genalice, said in a statement. "Our partnership offers a new reality in which large volumes can be analyzed close to real time, enabling truly important data interpretation and data mining of genomic variants of interest in a cost-effective manner."